A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With Intravenous Gemcitabine and Abraxane in Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs VCN 01 (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors VCN Biosciences
- 03 Sep 2019 According to a VCN Bioscience media release, data from this trial will be presented at the annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September -1 October 2019.
- 27 Sep 2018 Status changed from active, no longer recruiting to completed.
- 02 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Sep 2018.